For instance, patients with high levels of CD8+ T cell infiltration may benefit from immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 therapies, which have shown efficacy in other cancers with a similar immune profile 71,72. This evidence concerns the gene CTLA4 and cancer.